Current Illinois CancerCare Clinical Trials

Testing Ramipril to Prevent Memory Loss in People With Glioblastoma

Study Number: WF-1801

Study Summary:
This study is to determine if an oral drug called Ramipril can lower the chance of memory loss in patients with glioblastoma getting chemoradiation. Patients will take Ramipril during chemoradiation and continue until 4 months post-treatment. Memory loss will be assessed using several neurocognitive tests throughout the duration of the study.

Status: Open

Study Coordinator(s)
  • Courtney, 309-243-3660 cbrown@illinoiscancercare.com
  • Kiana, 309-243-3623, kshawd@illinoiscancercare.com
  • Hannah S, 309-243-3603, hshearburn@illinoiscancercare.com

Study Link

« Search Again